Gemcitabine for the treatment of advanced nonsmall cell lung cancer

References

• JemalASiegelRWardEHaoYXuJMurrayTCancer statistics, 2008CA Cancer J Clin2008582719618287387
   PubMed Web of Science ®Google Scholar
• PfisterDGJohnsonDHAzzoliCGSauseWSmithTJBakerSJrAmerican Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003J Clin Oncol200422233035314691125
   PubMed Web of Science ®Google Scholar
• MiniENobiliSCaciagliBLandiniIMazzeiTCellular pharmacology of gemcitabineAnn Oncol200617Suppl 5v7v1216807468
   PubMed Web of Science ®Google Scholar
• PetersGJvan der WiltCLvan MoorselCJKroepJRBergmanAMAcklandSPBasis for effective combination cancer chemotherapy with antimetabolitesPharmacol Ther2000872–32275311008002
   PubMed Web of Science ®Google Scholar
• Gemcitabine FDA-approved label; 2005http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020509s033lbl.pdf
   Google Scholar
• AndersonHLundBBachFThatcherNWallingJHansenHHSingle-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II studyJ Clin Oncol1994129182118268083706
   PubMed Web of Science ®Google Scholar
• GrunewaldRKantarjianHKeatingMJAbbruzzeseJTarassoffPPlunkettWPharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (Gemcitabine) administration in leukemiaCancer Res19905021682368262208147
   PubMed Web of Science ®Google Scholar
• AbbruzzeseJLGrunewaldRWeeksEAGravelDAdamsTNowakBA phase I clinical, plasma, and cellular pharmacology study of gemcitabineJ Clin Oncol1991934914981999720
   PubMed Web of Science ®Google Scholar
• CeribelliAGridelliCDe MarinisFFabiAGamucciTCortesiEProlonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatinCancer200398233734312872354
   PubMed Web of Science ®Google Scholar
• CappuzzoFNovelloSDe MarinisFSelvaggiGScagliottiGVBarbieriFA randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapyLung Cancer200652331932516630670
   PubMed Web of Science ®Google Scholar
• GridelliCDe MaioEBarberaSSannicoloMPiazzaEPiantedosiFThe MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patientsLung Cancer2008611677218683299
   PubMed Web of Science ®Google Scholar
• Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative GroupBMJ199531170108999097580546
   PubMed Web of Science ®Google Scholar
• CrinoLScagliottiGVRicciSDe MarinisFRinaldiMGridelliCGemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer ProjectJ Clin Oncol199917113522353010550150
   PubMed Web of Science ®Google Scholar
• CardenalFLopez-CabrerizoMPAntonAAlberolaVMassutiBCarratoARandomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancerJ Clin Oncol1999171121810458212
   PubMed Web of Science ®Google Scholar
• SandlerABNemunaitisJDenhamCvon PawelJCormierYGatzemeierUPhase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancerJ Clin Oncol200018112213010623702
   PubMed Web of Science ®Google Scholar
• SchillerJHHarringtonDBelaniCPLangerCSandlerAKrookJComparison of four chemotherapy regimens for advanced nonsmall-cell lung cancerN Engl J Med20023462929811784875
   PubMed Web of Science ®Google Scholar
• ScagliottiGVDe MarinisFRinaldiMCrinoLGridelliCRicciSPhase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancerJ Clin Oncol200220214285429112409326
   PubMed Web of Science ®Google Scholar
• ScagliottiGVParikhPvon PawelJBiesmaBVansteenkisteJManegoldCPhase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancerJ Clin Oncol200826213543355118506025
   PubMed Web of Science ®Google Scholar
• SchillerJTildenDAristidesMLeesMKielhornAManiadakisNRetrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in EuropeLung Cancer200443110111214698544
   PubMed Web of Science ®Google Scholar
• LeesMAristidesMManiadakisNMcKendrickJBotwoodNStephensonDEconomic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancerPharmacoeconomics200220532533711994042
   PubMed Web of Science ®Google Scholar
• NovelloSKielhornAStynesGSelvaggiGDe MarinisFMaestriACost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in ItalyLung Cancer200548337938715893007
   PubMed Web of Science ®Google Scholar
• PimentelFLBhallaSLaranjeiraLGuerreiroMCost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancerLung Cancer2006523365367116650499
   PubMed Web of Science ®Google Scholar
• GridelliCGalloCShepherdFAIllianoAPiantedosiFRobbiatiSFGemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials GroupJ Clin Oncol200321163025303412837810
   PubMed Web of Science ®Google Scholar
• LaackEDickgreberNMullerTKnuthABenkJLorenzCRandomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study GroupJ Clin Oncol200422122348235615197195
   PubMed Web of Science ®Google Scholar
• KubotaKKawaharaMOgawaraMNishiwakiYKomutaKMinatoKVinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III studyLancet Oncol20089121135114219013107
   PubMed Web of Science ®Google Scholar
• GeorgouliasVArdavanisATsiafakiXAgelidouAMixalopoulouPAnagnostopoulouOVinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trialJ Clin Oncol200523132937294515728228
   PubMed Web of Science ®Google Scholar
• GeorgouliasVAndroulakisNKotsakisAHatzidakiDSyrigosKPolyzosADocetaxel versus docetaxel plus gemcitabine as frontline treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trialLung Cancer2008591576317765354
   PubMed Web of Science ®Google Scholar
• PujolJLBretonJLGervaisRRebattuPDepierreAMorereJFGemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatinAnn Oncol200516460261015741225
   PubMed Web of Science ®Google Scholar
• KosmidisPMylonakisNNicolaidesCKalophonosCSamantasEBoukovinasJPaclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trialJ Clin Oncol200220173578358512202657
   PubMed Web of Science ®Google Scholar
• KosmidisPAKalofonosHPChristodoulouCSyrigosKMakatsorisTSkarlosDPaclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology GroupAnn Oncol200819111512217938425
   PubMed Web of Science ®Google Scholar
• SmitEFvan MeerbeeckJPLianesPDebruyneCLegrandCSchramelFThree-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group – EORTC 08975J Clin Oncol200321213909391714581415
   PubMed Web of Science ®Google Scholar
• D’AddarioGPintilieMLeighlNBFeldRCernyTShepherdFAPlatinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literatureJ Clin Oncol200523132926293615728229
   PubMed Web of Science ®Google Scholar
• AlbainKSCrowleyJJLeBlancMLivingstonRBSurvival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experienceJ Clin Oncol199199161816261651993
   PubMed Web of Science ®Google Scholar
• Giovanazzi-BannonSRademakerALaiGBensonAB3rdTreatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center studyJ Clin Oncol19941211244724527964962
   PubMed Web of Science ®Google Scholar
• Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study GroupJ Natl Cancer Inst199991166729890172
   PubMedGoogle Scholar
• RicciSAntonuzzoAGalliLTibaldiCBertuccelliMLopes PegnaAGemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: a multicenter phase II studyLung Cancer2000272758010688490
   PubMed Web of Science ®Google Scholar
• MartoniADi FabioFGuaraldiMPianaERaminiRLelliGProspective phase II study of single-agent gemcitabine in untreated elderly patients with stage IIIB/IV non-small-cell lung cancerAm J Clin Oncol200124661461711801766
   PubMed Web of Science ®Google Scholar
• GridelliCCigolariSGalloCManzioneLIannielloGPFrontiniLActivity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trialLung Cancer2001312–327728411165408
   PubMed Web of Science ®Google Scholar
• FrasciGLorussoVPanzaNComellaPNicolellaGBiancoAGemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trialLung Cancer200134Suppl 4S65S6911742706
   PubMed Web of Science ®Google Scholar
• GridelliCPerroneFGalloCCigolariSRossiAPiantedosiFChemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trialJ Natl Cancer Inst200395536237212618501
   PubMed Web of Science ®Google Scholar
• ComellaPFrasciGCarnicelliPMassiddaBBuzziFFilippelliGGemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patientsBr J Cancer200491348949715266334
   PubMed Web of Science ®Google Scholar
• SyrigosKNKarapanagiotouECharpidouADilanaKDannosIDionellisGBiweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer: a phase II studyJ Chemother200719443844317855189
   PubMed Web of Science ®Google Scholar
• ComellaPPutzuCMassiddaBCondemiGDe CataldisGBarbatoEIntra-patient alternated dose escalation of paclitaxel and gemcitabine versus paclitaxel followed by fixed dose rate infusion of gemcitabine in fit elderly non-small cell lung cancer patients. A Southern Italy Cooperative Oncology Group randomised phase II trialLung Cancer200756226327117298853
   PubMed Web of Science ®Google Scholar
• PinoMSGamucciTMansuetoGTrapassoTNarducciFGiampaoloMAA phase II study of biweekly paclitaxel (P) and gemcitabine (G), followed by maintenance weekly paclitaxel in elderly patients with advanced non-small cell lung cancer (NSCLC)Lung Cancer200860338138618068853
   PubMed Web of Science ®Google Scholar
• PallisAGPolyzosABoukovinasIAgelidouALamvakasLTsiafakiXPooled analysis of elderly patients with non-small cell lung cancer treated with front line docetaxel/gemcitabine regimen: the Hellenic Oncology Research Group experienceJ Thorac Oncol20083550551018449003
   PubMed Web of Science ®Google Scholar
• HainsworthJDSpigelDRFarleyCShipleyDLBeardenJDGandhiJWeekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research NetworkCancer200711092027203417823908
   PubMed Web of Science ®Google Scholar
• RussoARizzoSFulfaroFAdamoVSantiniDVincenziBGemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysisCancer200911591924193119235250
   PubMed Web of Science ®Google Scholar
• FukuokaMYanoSGiacconeGTamuraTNakagawaKDouillardJYMulti-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]J Clin Oncol200321122237224612748244
   PubMed Web of Science ®Google Scholar
• KrisMGNataleRBHerbstRSLynchTJJrPragerDBelaniCPEfficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trialJAMA2003290162149215814570950
   PubMed Web of Science ®Google Scholar
• SoulieresDSenzerNNVokesEEHidalgoMAgarwalaSSSiuLLMulticenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neckJ Clin Oncol2004221778514701768
   PubMed Web of Science ®Google Scholar
• Perez-SolerRPhase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in nonsmall-cell lung cancerClin Lung Cancer20046Suppl 1S20S2315638953
   PubMedGoogle Scholar
• ShepherdFARodrigues PereiraJCiuleanuTTanEHHirshVThongprasertSErlotinib in previously treated non-small-cell lung cancerN Engl J Med2005353212313216014882
   PubMed Web of Science ®Google Scholar
• GiacconeGHerbstRSManegoldCScagliottiGRosellRMillerVGefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 1J Clin Oncol200422577778414990632
   PubMed Web of Science ®Google Scholar
• HerbstRSGiacconeGSchillerJHNataleRBMillerVManegoldCGefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2J Clin Oncol200422578579414990633
   PubMed Web of Science ®Google Scholar
• HerbstRSPragerDHermannRFehrenbacherLJohnsonBESandlerATRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancerJ Clin Oncol200523255892589916043829
   PubMed Web of Science ®Google Scholar
• GatzemeierUPluzanskaASzczesnaAKaukelERoubecJDe RosaFPhase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation TrialJ Clin Oncol200725121545155217442998
   PubMed Web of Science ®Google Scholar
• LynchTJBellDWSordellaRGurubhagavatulaSOkimotoRABranniganBWActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med2004350212129213915118073
   PubMed Web of Science ®Google Scholar
• CappuzzoFHirschFRRossiEBartoliniSCeresoliGLBemisLEpidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancerJ Natl Cancer Inst200597964365515870435
   PubMed Web of Science ®Google Scholar
• CappuzzoFLigorioCJannePAToschiLRossiETrisoliniRProspective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trialJ Clin Oncol200725162248225517538169
   PubMed Web of Science ®Google Scholar
• PirkerRPereiraJRSzczesnaAvon PawelJKrzakowskiMRamlauRCetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialLancet200937396741525153119410716
   PubMed Web of Science ®Google Scholar
• ButtsCABodkinDMiddlemanELEnglundCWEllisonDAlamYRandomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancerJ Clin Oncol200725365777578418089875
   PubMed Web of Science ®Google Scholar
• MaurizJLGonzalez-GallegoJAntiangiogenic drugs: current knowledge and new approaches to cancer therapyJ Pharm Sci200897104129415418200520
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCBrahmerJSchillerJHDowlatiAPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
   PubMed Web of Science ®Google Scholar
• ReckMvon PawelJZatloukalPRamlauRGorbounovaVHirshVPhase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAilJ Clin Oncol20092781227123419188680
   PubMed Web of Science ®Google Scholar
• AchiwaHOguriTSatoSMaedaHNiimiTUedaRDeterminants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancerCancer Sci200495975375715471562
   PubMed Web of Science ®Google Scholar
• SebastianiVRicciFRubio-ViqueiraBKuleszaPYeoCJHidalgoMImmunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survivalClin Cancer Res20061282492249716638857
   PubMed Web of Science ®Google Scholar
• LambaJKCrewsKPoundsSSchuetzEGGreshamJGandhiVPharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variantsJ Pharmacol Exp Ther2007323393594517855478
   PubMed Web of Science ®Google Scholar
• Al-MadhounASvan der WiltCLLovesWJPadronJMErikssonSTalianidisIDetection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2′-2′-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000Biochem Pharmacol200468460160915276067
   PubMed Web of Science ®Google Scholar
• SevePMackeyJRIsaacSTredanOSouquetPJPerolMcN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancerLung Cancer200549336337015923058
   PubMed Web of Science ®Google Scholar
• BengalaCGuarneriVGiovannettiELencioniMFontanaEMeyVProlonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinomaBr J Cancer2005931354015986033
   PubMed Web of Science ®Google Scholar
• GiovannettiEDel TaccaMMeyVFunelNNannizziSRicciSTranscription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabineCancer Res20066673928393516585222
   PubMed Web of Science ®Google Scholar
• van HaperenVWVeermanGVermorkenJBPinedoHMPetersGRegulation of phosphorylation of deoxycytidine and 2′,2′-difluorodeoxycytidine (gemcitabine); effects of cytidine 5’-triphosphate and uridine 5’-triphosphate in relation to chemosensitivity for 2′,2′-difluorodeoxycytidineBiochem Pharmacol19965179119188651941
   PubMed Web of Science ®Google Scholar
• BergmanAMPinedoHMJongsmaAPBrouwerMRuiz van HaperenVWVeermanGDecreased resistance to gemcitabine (2’,2’-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinaseBiochem Pharmacol19995743974069933028
   PubMed Web of Science ®Google Scholar
• YonemoriKUenoHOkusakaTYamamotoNIkedaMSaijoNSevere drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatinClin Cancer Res20051172620262415814642
   PubMed Web of Science ®Google Scholar
• SugiyamaEKaniwaNKimSRKikura-HanajiriRHasegawaRMaekawaKPharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphismJ Clin Oncol2007251324217194903
   PubMed Web of Science ®Google Scholar
• RosellRFelipETaronMMajoJMendezPSanchez-RoncoMGene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgeryClin Cancer Res200410(12 Pt 2):4215s4219s15217961
   PubMed Web of Science ®Google Scholar
• RosellRDanenbergKDAlberolaVBeplerGSanchezJJCampsCRibonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patientsClin Cancer Res20041041318132514977831
   PubMed Web of Science ®Google Scholar
• CeppiPVolanteMNovelloSRapaIDanenbergKDDanenbergPVERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabineAnn Oncol200617121818182516980606
   PubMed Web of Science ®Google Scholar
• SouglakosJBoukovinasITaronMMendezPMavroudisDTripakiMRibonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabineBr J Cancer200898101710171518414411
   PubMed Web of Science ®Google Scholar
• ZhengZChenTLiXHauraESharmaABeplerGDNA synthesis and repair genes RRM1 and ERCC1 in lung cancerN Engl J Med2007356880080817314339
   PubMed Web of Science ®Google Scholar
• BeplerGZhengZGautamASharmaSCantorASharmaARibonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevanceLung Cancer200547218319215639717
   PubMed Web of Science ®Google Scholar
• KwonWSRhaSYChoiYHLeeJOParkKHJungJJRibonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell linesPharmacogenet Genomics200616642943816708051
   PubMed Web of Science ®Google Scholar
• OlaussenKADunantAFouretPBrambillaEAndreFHaddadVDNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapyN Engl J Med20063551098399116957145
   PubMed Web of Science ®Google Scholar
• SimonGSharmaALiXHazeltonTWalshFWilliamsCFeasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancerJ Clin Oncol200725192741274617602079
   PubMed Web of Science ®Google Scholar